Teva launches generic Ranexa
Teva is introducing its generic Ranexa (ranolazine extended-release tablets). The generic of Gilead's branded product is available in 500-mg and 1000-mg dosage strengths.
Teva's generic Ranexa is indicated for the treatment of chronic angina.
“We’re pleased to add to our portfolio of generic medicines that offer another treatment option for people living with chronic conditions like angina,” Teva executive vice president and head of North America commercial Brendan O’Grady said.
Ranolazine extended-release tablets had a market value of nearly $938 million, according to IQVIA data as of February 2019.
Teva's generic Ranexa is indicated for the treatment of chronic angina.
“We’re pleased to add to our portfolio of generic medicines that offer another treatment option for people living with chronic conditions like angina,” Teva executive vice president and head of North America commercial Brendan O’Grady said.
Ranolazine extended-release tablets had a market value of nearly $938 million, according to IQVIA data as of February 2019.